Morgan Stanley’s Sunshine Biopharma SBFM Stock Holding History

Morgan Stanley’s Portfolio SBFM Stock Details SBFM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$808	Sell	19 -54	-74%	-$6.92K	﹤0.01%	7538
2026 Q1	$15.2K	Hold	73	–	–	﹤0.01%	6823
2025 Q4	$18K	Buy	73 +54	+284%	+$17.1K	﹤0.01%	6725
2025 Q3	$5.71K	Hold	19	–	–	﹤0.01%	7057
2025 Q2	$5.52K	Hold	19	–	–	﹤0.01%	7010
2025 Q1	$7.32K	Sell	19 -19	-50%	-$9.6K	﹤0.01%	6895
2024 Q4	$22.9K	Buy	+38	New	+$21.6K	﹤0.01%	6529
2024 Q3	–	Hold	0	–	–	–	7903
2024 Q2	–	Hold	0	–	–	–	7246
2023 Q4	–	Hold	0	–	-$8	–	7899
2023 Q3	–	Hold	0	–	–	–	7570
2023 Q2	–	Hold	0	–	–	–	7594
2023 Q1	–	Hold	0	–	–	–	7643
2022 Q3	–	Hold	0	–	-$7K	–	7847
2022 Q2	–	Hold	0	–	–	–	7326

Other funds holding SBFM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $140B AUM 46.34% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Strive Financial Group Carmel, Indiana $230M AUM

TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

Morgan Stanley's SBFM Position: Q2 2026 in Review

Morgan Stanley reduced its Sunshine Biopharma (SBFM) stake by 74% in Q2 2026, selling an estimated $6.92K and leaving 19 shares worth $808. The position accounts for ﹤0.01% of the portfolio, ranked #7538.

Morgan Stanley first reported a position in SBFM in Q4 2024 and has held it in 7 quarters since. The position peaked at $22.9K in Q4 2024. 3 funds tracked by Wall St. Rank hold SBFM as of Q2 2026.

Morgan Stanley held 19 shares of Sunshine Biopharma worth $808 as of Q2 2026.
Morgan Stanley sold 54 Sunshine Biopharma shares in Q2 2026, an estimated $6.92K.
Sunshine Biopharma made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #7538 holding.
Morgan Stanley first reported a position in Sunshine Biopharma in Q4 2024 and has held it in 7 quarters since.
Morgan Stanley's Sunshine Biopharma position peaked at $22.9K in Q4 2024.
3 funds tracked by Wall St. Rank held Sunshine Biopharma as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.